B
Beijing Puqi Pharmaceutical Technology
Develops and issues pharmaceutical products with a focus on innovative medical solutions
About Beijing Puqi Pharmaceutical Technology
Established in 2016, Beijing Puqi Pharmaceutical Technology, also known as PrimeGene (Beijing), operates as a privately held pharmaceutical company focused on drug discovery and development. The firm is strategically centered on creating new drugs for immune and inflammatory diseases, with a specific emphasis on treatments for skin, ophthalmology, rhinology, and respiratory system conditions. The company's business model encompasses innovative drug research, the development of clinically valuable generic drugs, and pharmaceutical industrialization.
The company's core activities involve the research, development, and commercialization of a pipeline of pharmaceutical products. This drug pipeline includes small molecule drugs targeting immune system diseases, nervous system diseases, neoplasms, infectious diseases, and metabolic disorders. One of its notable drug candidates is Pumecitinib, a JAK tyrosine kinase inhibitor. The company is actively engaged in clinical trials to advance its products toward regulatory approval and market entry. The business generates revenue but is also backed by venture capital, having raised funds to support its R&D and commercialization efforts.
As a privately backed entity, Beijing Puqi Pharmaceutical Technology has secured funding from multiple investors. It has completed several funding rounds, including a Series B round in early 2025, to finance its operations and drug development programs. The company maintains a portfolio of patents related to its discoveries, such as polymorphs of JAK tyrosine kinase inhibitors and their preparation methods. Its client base would primarily consist of patients and healthcare providers upon successful commercialization of its drug candidates, operating within the global biopharmaceutical market. Its main office is located in the Fengtai District of Beijing.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2025 | $41M | $165M | Beijing Shunxi Equity Investment Fund · E-Town Capital · North Science and Technology Construction | ↗ |
| LATE VCOther financing | May 2024 | $14M | $55M | Shunxi Private Equity Fund Management | ↗ |
Growth signals
Latest recorded traffic for Beijing Puqi Pharmaceutical Technology is 160 monthly website visits, up 128.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Puqi Pharmaceutical Technology in its local ecosystem
The Beijing Puqi Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- BFBeijing Shunxi Equity Investment Fund
E-Town Capital- NCNorth Science and Technology Construction
Series B and later1 investor entered at this stage
- SMShunxi Private Equity Fund Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Puqi Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Puqi Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









